| Summary: | The prevalence of patients hospitalized in ICUs with COVID-19 and co-infected by pathogenic bacteria is relevant in this study, considering the integrality of treatment. This systematic review assesses the prevalence of co-infection in patients admitted to ICUs with SARS-CoV-2 infection, using the PRISMA guidelines. We examined the results of the PubMed, Embase, and SciELO databases, searching for published English literature from December 2019 to December 2021. A total of 542 rec ords were identified, but only 38 were eligible and, and of these only 10 were included. The tabulated studies represented a sample group of 1394 co-infected patients. In total, 35%/138 of the patients were co-infected with <i>Enterobacter</i> spp., 27% (17/63) were co-infected with methicillin-sensitive <i>Staphylococ cus aureus</i>, 21% (84/404) were co-infected with <i>Klebsiella</i> spp., 16% (47/678) of patients were co-infected with coagulase-negative <i>Staphylococcus</i>, 13% (10/80) co-infected with <i>Escherichia coli</i> (ESBL), and 3% (30/1030) of patients were co-infected with <i>Pseudomonas aeruginosa</i>. The most common co-infections were related to blood flow; although in the urinary and respiratory tracts of patients <i>Streptococcus pneumoniae</i> was found in 57% (12/21) of patients, coagulase negative <i>Staphylococcus</i> in 44% (7/16) of patients, and <i>Escherichia coli</i> was found in 37% (11/29) of patients. The present research demonstrated that co-infections caused by bacteria in patients with COVID-19 are a concern.
|
|---|